Gibco™ Hybridoma-SFM, powder, 10L

Gibco™ Hybridoma-SFM, Powder is a serum-free, very low-protein dry format medium specifically developed to support the robust growth and antibody production of hybridomas and recombinant myeloma cell lines. Upon reconstitution, it becomes a complete, ready-to-use medium that supports both stationary and suspension cultures, including cholesterol-dependent lines such as NS0 (when supplemented with 250× Cholesterol Lipid Concentrate).

With a total protein content of less than 20 μg/mL, this formulation simplifies downstream purification of monoclonal antibodies (mAbs), making it ideal for both research and preclinical biomanufacturing. It contains L-glutamine and requires no additional supplementation post-reconstitution.

Manufactured in a cGMP-compliant, ISO 13485-certified facility in Grand Island, NY, this product is eligible for FDA regulatory submissions via a Type II Drug Master File (DMF).

Key Features

• Powdered Format: Convenient for bulk preparation of 10 L of complete, serum-free medium.
• Low Protein Content: <20 µg/mL for reduced background and simplified antibody purification.
• Serum-Free Formulation: Supports defined and consistent cell culture conditions.
• Supports IgG Production: Promotes high cell densities and productivity in hybridomas and recombinant myelomas.
• Complete Medium Upon Reconstitution: Includes L-glutamine; no further supplementation needed.
• Regulatory Ready: Supported by cGMP manufacturing and Type II DMF for FDA submission.

Applications

• Monoclonal Antibody Production:
  • Ideal for culturing hybridomas and myelomas in mAb generation workflows.
• Serum-Free Cell Culture:
  • Suitable for workflows requiring serum-free, defined media.
• Bioprocessing and Preclinical Manufacturing:
  • Clean formulation supports scale-up and regulatory compliance.
• Protein Purification Simplification:
  • Low protein content enables easier downstream purification of target antibodies.

Specifications

Gibco™ Hybridoma-SFM, Powder delivers a reliable, scalable, and regulatory-compliant solution for hybridoma-based monoclonal antibody production in serum-free conditions. Its low protein profile and complete post-reconstitution formulation make it ideal for antibody discovery and manufacturing processes requiring high purity and reproducibility.